Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 127-135

  Haddad, Marwan S ^a   Zelenev, Alexei ^b   Altice, Frederick L ^b,c  

^a USA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Buprenorphine; Community health centers; Federally qualified health centers; Healthcare utilization; Implementation science; Opioid dependence; Substance abuse

Indexed keywords

BUPRENORPHINE; COCAINE; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; COCAINE DEPENDENCE; COHORT ANALYSIS; COMORBIDITY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CENTER; HEALTH PROGRAM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OBSERVATIONAL STUDY; OPIATE ADDICTION; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TREATMENT OUTCOME; UNITED STATES;

ADULT; BUPRENORPHINE; COHORT STUDIES; CONNECTICUT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT PROTECTION AND AFFORDABLE CARE ACT; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84878582939     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.008     Document Type: Article

References (43)

1. Alford D.P., LaBelle C.T., Kretsch N., Bergeron A., Winter M., Botticelli M., Samet J.H. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch. Intern. Med. 2011, 171:425-431.
2. Alford D.P., LaBelle C.T., Richardson J.M., O'Connell J.J., Hohl C.A., Cheng D.M., Samet J.H. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J. Gen. Intern. Med. 2007, 22:171-176.
3. Alford D.P., Saitz R., LaBelle C., Samet J.H. Buprenorphine Initiation and Maintenance in Primary Care: A Successful Interdisciplinary Approach. Buprenorphine in the Primary HIV Care Setting 2004, Forum for Collaborative HIV Research, Washington, DC.
4. Altice F.L., Bruce R.D., Lucas G.M., Lum P.J., Korthuis P.T., Flanigan T.P., Cunningham C.O., Sullivan L.E., Vergara-Rodriguez P., Fiellin D.A., Cajina A., Botsko M., Nandi V., Gourevitch M.N., Finkelstein R., Collaborative B. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 2011, 56 Suppl.(1):S22-S32.
5. Altice F.L., Kamarulzaman A., Soriano V.V., Schechter M., Friedland G.H. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010, 376:59-79.
6. Altice F.L., Sullivan L.E., Smith-Rohrberg D., Basu S., Stancliff S., Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin. Infect. Dis. 2006, 43 Suppl.(4):S178-S183.
7. Bae J.W., Guyer W., Grimm K., Altice F.L. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25:279-290.
8. Barry D.T., Irwin K.S., Jones E.S., Becker W.C., Tetrault J.M., Sullivan L.E., Hansen H., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Integrating buprenorphine treatment into office-based practice: a qualitative study. J. Gen. Intern. Med. 2009, 24:218-225.
9. Basu S., Smith-Rohrberg D., Bruce R.D., Altice F.L. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin. Infect. Dis. 2006, 42:716-721.
10. Bruce R.D., Dvoryak S., Sylla L., Altice F.L. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-programme description and policy implications. Int. J. Drug Policy 2007, 18:326-328.
11. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: the international experience. Clin. Infect. Dis. 2006, 43:S197-S215.
12. Center for Substance Abuse Treatment, 2004. In: Substance Abuse and Mental Health Services Administration (SAMHSA) (Ed)., Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Department of Health and Human Services, Rockville, MD.
13. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., Fry-Smith A., Day E., Lintzeris N., Roberts T., Burls A., Taylor R.S. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess. 2007, 11(1-171):iii-iv.
14. Copenhaver M.M., Bruce R.D., Altice F.L. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am. J. Drug Alcohol Abuse 2007, 33:643-654.
15. Cunningham C., Giovanniello A., Sacajiu G., Whitley S., Mund P., Beil R., Sohler N. Buprenorphine treatment in an urban community health center: what to expect. Fam. Med. 2008, 40:500-506.
16. Cunningham C.O., Giovanniello A., Li X., Kunins H.V., Roose R.J., Sohler N.L. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J. Subst. Abuse Treat. 2011, 40:349-356.
17. Enders C.K. Applied Missing Data Analysis 2010, Guilford Press, New York.
18. Fareed A., Vayalapalli S., Casarella J., Drexler K. Effect of buprenorphine dose on treatment outcome. J. Addict. Dis. 2012, 31:8-18.
19. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Barry D.T., O'Connor P.G., Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am. J. Addict. 2008, 17:116-120.
20. Friedman S.R., Tempalski B., Brady J.E., Friedman J.J., Cooper H.L., Flom P.L., McGrath M.M., Gostnell K., Des Jarlais D.C. Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America. Int. J. Drug Policy 2007, 18:475-485.
21. Gunderson E.W., Wang X.Q., Fiellin D.A., Bryan B., Levin F.R. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict. Behav. 2010, 35:537-540.
22. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005, 23:77-91.
23. Ing E.C., Bae J.W., Maru D.S., Altice F.L. Medication persistence of HIV-infected drug users on directed administered antiretroviral therapy. AIDS Behav. 2011, (Epub ahead of print).
24. Jackman S. Estimation and inference via Bayesian simulation: an introduction to Markov chain Monte Carlo. Am. J. Polit. Sci. 2000, 44:375.
25. Kakko J., Gronbladh L., Svanborg K.D., von Wachenfeldt J., Ruck C., Rawlings B., Nilsson L.H., Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am. J. Psychiatry 2007, 164:797-803.
26. Kakko J., Svanborg K.D., Kreek M.J., Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised placebo-controlled trial. Lancet 2003, 361:662-668.
27. Korthuis P.T., Fiellin D.A., Fu R., Lum P.J., Altice F.L., Sohler N., Tozzi M.J., Asch S.M., Botsko M., Fishl M., Flanigan T.P., Boverman J., McCarty D., Collaborative B. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J. Acquir. Immune Defic. Syndr. 2011, 56 Suppl.(1):S83-S90.
28. Krantz M.J., Mehler P.S. Treating opioid dependence. Growing implications for primary care. Arch. Intern. Med. 2004, 164:277-288.
29. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
30. Mintzer I.L., Eisenberg M., Terra M., MacVane C., Himmelstein D.U., Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann. Fam. Med. 2007, 5:146-150.
31. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22:527-530.
32. Netherland J., Botsko M., Egan J.E., Saxon A.J., Cunningham C.O., Finkelstein R., Gourevitch M.N., Renner J.A., Sohler N., Sullivan L.E., Weiss L., Fiellin D.A. Factors affecting willingness to provide buprenorphine treatment. J. Subst. Abuse Treat. 2009, 36:244-251.
33. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., Rounsaville B.J., Pakes J.A., Schottenfeld R.S. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med. 1998, 105:100-105.
34. Parran T.V., Adelman C.A., Merkin B., Pagano M.E., Defranco R., Ionescu R.A., Mace A.G. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010, 106:56-60.
35. Penberthy J.K., Ait-Daoud N., Vaughan M., Fanning T. Review of treatment for cocaine dependence. Curr. Drug Abuse Rev. 2010, 3:49-62.
36. Petry N.M., Barry D., Alessi S.M., Rounsaville B.J., Carroll K.M. A randomized trial adapting contingency management targets based on initial abstinence status of cocaine-dependent patients. J. Consult. Clin. Psychol. 2012, 80:276-285.
37. SAMHSA Results from the 2010 National Survey on Drug Use and Health: National Findings 2011, Substance Abuse and Mental Health Services Agency, Rockville, MD. Office of Applied Studies (Ed.).
38. Schwarz R., Zelenev A., Bruce R.D., Altice F.L. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J. Subst. Abuse Treat. 2012, 43(4):451-457.
39. Soeffing J.M., Martin L.D., Fingerhood M.I., Jasinski D.R., Rastegar D.A. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J. Subst. Abuse Treat. 2009, 37:426-430.
40. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. J. Gen. Intern. Med. 2005, 20:1038-1041.
41. Sullivan L.E., Botsko M., Cunningham C.O., O'Connor P.G., Hersh D., Mitty J., Lum P.J., Schottenfeld R.S., Fiellin D.A. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J. Acquir. Immune Defic. Syndr. 2011, 56 Suppl.(1):S54-S61.
42. Sylla L., Bruce R.D., Kamarulzaman A., Altice F.L. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int. J. Drug Policy 2007, 18:306-312.
43. Weiss L., Netherland J., Egan J.E., Flanigan T.P., Fiellin D.A., Finkelstein R., Altice F.L., Collaborative B. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J. Acquir. Immune Defic. Syndr. 2011, 56 Suppl.(1):S68-S75.